Location Directory

Clinical trials in Philadelphia, Pennsylvania

This page shows live ClinicalTrials.gov search results for Philadelphia, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

17134

Shown on this page

Current sort

Institutions in Philadelphia

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search

Conditions: Pulmonary Embolism, Pulmonary Thromboembolism
Interventions: FlowTriever System, Standard of Care; Device · Procedure
Lead sponsor: Inari Medical; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 16
States / cities: New Haven, Connecticut • Orlando, Florida • Sarasota, Florida + 11 more

Conditions: Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression, Prevention & Control, Premature Atherosclerosis
Interventions: Rosuvastatin 20 Mg Oral Tablet, Colchicine 0.5 MG Oral Tablet Once Daily, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 30 Years to 60 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 23
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 18 more

Conditions: Adjustment Disorder
Interventions: RE104 for Injection; Drug
Lead sponsor: Reunion Neuroscience Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 33
States / cities: Birmingham, Alabama • Tucson, Arizona • San Diego, California + 28 more

Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Interventions: Atumelnant, Placebo; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 15
States / cities: Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 12 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Verducatib, Placebo matching verducatib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Palma, California + 14 more

Conditions: Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
Interventions: nilotinib; Drug
Lead sponsor: Andrew J. Wagner, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 7
States / cities: Santa Monica, California • Stanford, California • Tampa, Florida + 3 more

Conditions: High Grade Serous Carcinoma
Interventions: Olaparib Pill, AZD6738; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Fibrosing Interstitial Lung Disease
Interventions: Nerandomilast, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • Baltimore, Maryland + 4 more

Conditions: Lymphedema of the Head and Neck
Interventions: Usual Care, In-Person LEF-SMP, Telehealth LEF-SMP; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Nashville, Tennessee

Conditions: Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
Interventions: ACDN-01; Drug
Lead sponsor: Ascidian Therapeutics, Inc; Industry
Eligibility: 12 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 11
States / cities: San Francisco, California • Gainesville, Florida • Miami, Florida + 8 more

Conditions: Major Depressive Disorder
Interventions: Brenipatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 35
States / cities: Phoenix, Arizona • Chino, California • Montclair, California + 28 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: INS1202; Genetic
Lead sponsor: Insmed Gene Therapy LLC; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Phoenix, Arizona • La Jolla, California • Palo Alto, California + 6 more

Clinical trials in Philadelphia, Pennsylvania

Filter and sort this location

Institutions in Philadelphia

Live official records

The PERSEVERE Study

PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)

Self-Management for Head and Neck Lymphedema and Fibrosis [PROMISE Trial]

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

A Study of Brenipatide in Participants With Major Depressive Disorder

A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)